Sean E. Aeder

Array ( [id] => 17399667 [patent_doc_number] => 20220041757 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS [patent_app_type] => utility [patent_app_number] => 17/504452 [patent_app_country] => US [patent_app_date] => 2021-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25188 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17504452 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18786368 [patent_doc_number] => 20230374453 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES [patent_app_type] => utility [patent_app_number] => 18/247878 [patent_app_country] => US [patent_app_date] => 2021-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 225099 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -82 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18247878 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18800051 [patent_doc_number] => 11833196 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-05 [patent_title] => Compositions and methods for delivery of biomacromolecule agents [patent_app_type] => utility [patent_app_number] => 17/501576 [patent_app_country] => US [patent_app_date] => 2021-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 39 [patent_no_of_words] => 38242 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17501576 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18784767 [patent_doc_number] => 20230372397 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES [patent_app_type] => utility [patent_app_number] => 18/247877 [patent_app_country] => US [patent_app_date] => 2021-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 223057 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -82 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18247877 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18971936 [patent_doc_number] => 20240052028 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-15 [patent_title] => ENHANCEMENT OF ANTI-TUMOR PHAGOCYTOSIS [patent_app_type] => utility [patent_app_number] => 18/030223 [patent_app_country] => US [patent_app_date] => 2021-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15740 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18030223 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18779137 [patent_doc_number] => 11820831 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-21 [patent_title] => Antibody binding to carbonic anhydrase and use thereof [patent_app_type] => utility [patent_app_number] => 17/489885 [patent_app_country] => US [patent_app_date] => 2021-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 40 [patent_no_of_words] => 20861 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17489885 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19447409 [patent_doc_number] => 20240307539 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => EGFR-TARGETING CHIMERIC ANTIGEN RECEPTOR [patent_app_type] => utility [patent_app_number] => 18/029400 [patent_app_country] => US [patent_app_date] => 2021-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9964 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18029400 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18770899 [patent_doc_number] => 20230365703 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => BISPECIFIC RECOMBINANT PROTEIN AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/026373 [patent_app_country] => US [patent_app_date] => 2021-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25041 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18026373 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18739663 [patent_doc_number] => 20230348627 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-02 [patent_title] => ANTI-4-1BB-ANTI-PD-L1 BISPECIFIC ANTIBODY, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/245694 [patent_app_country] => US [patent_app_date] => 2021-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17578 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18245694 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18753987 [patent_doc_number] => 20230357344 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => Interleukin 15 Constructs and Methods of Use [patent_app_type] => utility [patent_app_number] => 18/245654 [patent_app_country] => US [patent_app_date] => 2021-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14779 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18245654 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17505189 [patent_doc_number] => 20220098291 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => Treatment of Parkinson's Disease [patent_app_type] => utility [patent_app_number] => 17/471526 [patent_app_country] => US [patent_app_date] => 2021-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17162 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17471526 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18675170 [patent_doc_number] => 20230312759 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA [patent_app_type] => utility [patent_app_number] => 18/025208 [patent_app_country] => US [patent_app_date] => 2021-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29376 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 213 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18025208 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18964208 [patent_doc_number] => 11897959 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-13 [patent_title] => Anti-AXL antibodies, antibody fragments and their immunoconjugates and uses thereof [patent_app_type] => utility [patent_app_number] => 17/465968 [patent_app_country] => US [patent_app_date] => 2021-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 35 [patent_no_of_words] => 34520 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 295 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17465968 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18693079 [patent_doc_number] => 20230323470 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => METHODS OF TREATING CANCER BY ADMINISTERING A PD-1 INHIBITOR [patent_app_type] => utility [patent_app_number] => 18/042441 [patent_app_country] => US [patent_app_date] => 2021-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22113 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18042441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19904172 [patent_doc_number] => 12281168 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-22 [patent_title] => Binding molecule specific for LIF and use thereof [patent_app_type] => utility [patent_app_number] => 17/407264 [patent_app_country] => US [patent_app_date] => 2021-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 29 [patent_no_of_words] => 27325 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17407264 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17272973 [patent_doc_number] => 20210379171 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => OVARIAN CANCER VACCINES [patent_app_type] => utility [patent_app_number] => 17/404025 [patent_app_country] => US [patent_app_date] => 2021-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16706 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17404025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18649447 [patent_doc_number] => 20230295258 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => FUSION PROTEIN COMPRISING IL-12 AND ANTI-FAP ANTIBODY, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/041392 [patent_app_country] => US [patent_app_date] => 2021-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26386 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18041392 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17244779 [patent_doc_number] => 20210364522 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => METHODS FOR CAPTURING, ISOLATION, AND TARGETING OF CIRCULATING TUMOR CELLS AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 17/393892 [patent_app_country] => US [patent_app_date] => 2021-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23040 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17393892 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18692592 [patent_doc_number] => 20230322898 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => PHARMACEUTICAL COMPOSITION COMPRISING CELL EXPRESSING CHIMERIC RECEPTOR [patent_app_type] => utility [patent_app_number] => 18/018807 [patent_app_country] => US [patent_app_date] => 2021-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60265 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18018807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17227197 [patent_doc_number] => 20210353753 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-18 [patent_title] => Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/443780 [patent_app_country] => US [patent_app_date] => 2021-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22329 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17443780 [rel_patent_id] =>[rel_patent_doc_number] =>)